Pluronic P85 Increases Permeability of a Broad Spectrum of Drugs in Polarized BBMEC and Caco-2 Cell Monolayers
The DOI matches its Crossref record.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Lipids and Lipid-Based Formulations: Optimizing the Oral Delivery of Lipophilic Drugs
Porter, C. J. H., Trevaskis, N. L., & Charman, W. N. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2197 · Cited by 1,824
Strategies to Address Low Drug Solubility in Discovery and Development
Williams, H. D., Trevaskis, N. L., Charman, S. A., Shanker, R. M., Charman, W. N., Pouton, C. W., & Porter, C. J. H. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005660 · Cited by 1,570
Pluronic® block copolymers as novel polymer therapeutics for drug and gene delivery
Kabanov, A. V., Batrakova, E. V., & Alakhov, V. Y. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00009-3 · Cited by 1,474
Self-citationBatrakova, E. V., & Kabanov, A. V. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.04.013 · Cited by 1,278
“Inhibition of drug efflux transporters by Pluronic block copolymers enhanced transport of wide range of therapeutic agents across polarized brain microvessel endothelial cells and intestinal barrier cells in vitro [75] and in vivo [47].”
BackgroundSelf-citationAmphiphilic block copolymers for drug delivery
Adams, M. L., Lavasanifar, A., & Kwon, G. S. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10397 · Cited by 1,078
Modern methods for delivery of drugs across the blood–brain barrier
Chen, Y., & Liu, L. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.11.010 · Cited by 1,006
Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
Furtado, D., Björnmalm, M., Ayton, S., Bush, A. I., Kempe, K., & Caruso, F. (2018) · Advanced Materials · doi:10.1002/adma.201801362 · Cited by 708
Nanotechnological advances for the delivery of cns therapeutics.
Wong, H. L., Wu, X. Y., & Bendayan, R. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.10.007 · Cited by 488
Intestinal Permeation Enhancers
Aungst, B. J. (2000) · Journal of Pharmaceutical Sciences · doi:10.1002/(sici)1520-6017(200004)89:4<429::aid-jps1>3.0.co;2-j · Cited by 489
Polymeric micelles for drug delivery
Aliabadi, H. M., & Lavasanifar, A. (2006) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.3.1.139 · Cited by 446
Crossing the Blood–Brain Barrier: Recent Advances in Drug Delivery to the Brain
Patel, M. M., & Patel, B. M. (2017) · CNS Drugs · doi:10.1007/s40263-016-0405-9 · Cited by 430
“Pluronic P85, a Pluronic block copolymer, is one of the most widely studied P-gp inhibitors for its ability to enhance delivery of numerous anti-cancer agents such as etoposide, doxorubicin, and other drugs such as loperamide, digoxin, and valproic acid [62, 63].”
BackgroundMolecular and cellular mechanisms of pharmacoresistance in epilepsy
Remy, S., & Beck, H. (2006) · Brain · doi:10.1093/brain/awh682 · Cited by 406
Nanogels for Oligonucleotide Delivery to the Brain
Vinogradov, S. V., Batrakova, E. V., & Kabanov, A. V. (2004) · Bioconjugate Chemistry · doi:10.1021/bc034164r · Cited by 377
Self-citationLipid-based formulations for intestinal lymphatic delivery
O’Driscoll, C. M. (2002) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(02)00051-9 · Cited by 372
On the biodegradability of polyethylene glycol, polypeptoids and poly(2-oxazoline)s
Ulbricht, J., Jordan, R., & Luxenhofer, R. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.02.029 · Cited by 348
Mohan, P., & Rapoport, N. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100269f · Cited by 331
Kabanov, A. V., Batrakova, E. V., & Miller, D. W. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00176-x · Cited by 325
Self-citationAnticancer Polymeric Nanomedicines
Tong, R., & Cheng, J. (2007) · Polymer Reviews · doi:10.1080/15583720701455079 · Cited by 310
Batrakova, E. V., Li, S., Vinogradov, S. V., Alakhov, V. Y., Miller, D. W., & Kabanov, A. V. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29254-5 · Cited by 292
Self-citationSjögren, E., Abrahamsson, B., Augustijns, P., Becker, D., Bolger, M. B., Brewster, M., Brouwers, J., Flanagan, T., Harwood, M., Heinen, C., et al. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.02.010 · Cited by 279
Nanomedicine in the diagnosis and therapy of neurodegenerative disorders
Kabanov, A. V., & Gendelman, H. E. (2007) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2007.05.014 · Cited by 277
Self-citationPolymeric micelles in oral chemotherapy
Bromberg, L. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.01.018 · Cited by 264
Batrakova, E. V., Li, S., Alakhov, V. Y., Miller, D. W., & Kabanov, A. V. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.043307 · Cited by 263
Self-citationUltrasound-enhanced tumor targeting of polymeric micellar drug carriers
Gao, Z., Fain, H. D., & Rapoport, N. (2004) · Molecular Pharmaceutics · doi:10.1021/mp049958h · Cited by 121
Intelligent hydrogels for the oral delivery of chemotherapeutics
Bromberg, L. (2005) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2.6.1003 · Cited by 42
“Pluronic L61 is known to be a potent doxorubicin efflux suppressor at concentrations up to critical micellar concentration, above which the effects of Pluronics generally plateau and then decay [45-47].”
BackgroundPhysicochemical Characterization of Creatine N-Methylguanidinium Salts
Gufford, B. T., Sriraghavan, K., Miller, N. J., Miller, D. W., Gu, X., Vennerstrom, J. L., & Robinson, D. H. (2010) · Journal of Dietary Supplements · doi:10.3109/19390211.2010.491507 · Cited by 26
Self-citation
Metadata
- Authors
- Batrakova, E. V., Li, S., Miller, D. W., & Kabanov, A. V.
- Venue
- Pharmaceutical Research
- Published
- 1999-09
- Volume
- 16
- Issue
- 9
- Pages
- 1366-1372
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W105680442
- Cited by
- 206
- References
- 0
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.